1:22 PM
 | 
Jun 15, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lilly planning Phase III trials for Olumiant in lupus

Eli Lilly and Co. (NYSE:LLY) said it plans to start this year Phase III testing of Olumiant baricitinib to treat systemic lupus erythematosus (SLE) after reporting that the higher dose of the drug met the primary endpoint in a Phase II trial in the indication. Lilly presented the data at the European League Against Rheumatology meeting in Amsterdam.

Olumiant, a Janus kinase-1...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >